Implementation of the DDD/ClinGen OGT (CytoSure v3) Microarray
|
|
- Joanna Harper
- 6 years ago
- Views:
Transcription
1 Implementation of the DDD/ClinGen OGT (CytoSure v3) Microarray OGT UGM Birmingham 08/09/2016 Dom McMullan Birmingham Women's NHS Trust
2 WM chromosomal microarray (CMA) testing Population of ~6 million (10%) Chromosomal microarray (CMA) First-line test for all DD patients >5,000 per annum plus 15% growth Prenatal diagnosis (structural anomalies) Fetal pathology
3 Typical DD Pathway until 2015 CMA +/- single gene testing Deciphering Developmental Disorders (DDD) 12,000 trio exomes +/- ultra-high res arraycgh
4 Typical DD Pathway from 2016? CMA Clinical Exome (filtered) 100,000 whole genomes
5 Balancing factors for platform choice in Clinical Genomics Cost Detection rate Ease of analysis Throughput Discovery less important?
6 CMA platform choices Lowest cost, highest detection rate Available platforms within UK cost envelope: OGT / Agilent based 8x60k design (acgh) Affymetrix CytoScan 750k (SNP+CN based) Illumina CytoSNP 8x850k (SNP based)
7 DDD project Transformed Clinical Genetics in UK DECIPHER 12,000 exomes back to NHS Ended diagnostic odyssey Discovered >12 new genes Expedited interpretation skills the Genomic MDT DDG2P evidence based gene list
8 Evidence Bases for new OGT (v3.0) DDD array DDG2P gene list (n=>1,400) Disorder, Mechanism, Consequence and HI scores ISCA/ClinGen dosage sensitivity map ISCA/ClinVar submitted clinical cases DECIPHER recurrent syndromes OGT v3.0 60k CNV, 180k CNV and 180k CNV+SNP designs
9 DDG2P centric gene targeting ~300 Monoallelic / LoF genes at single exon resolution ~200 Monoallelic missense /uncertain genes at gene level Additional coverage in DECIPHER curated syndrome regions Evidence based backbone (ISCA/ClinGen pathogenic + HI score) Tier 1; ~120kb HI gene rich / reported pathogenic CNVs Tier 2; ~300kb Tier 3; ~500kb agenic / no reported pathogenic CNVs Theoretical resolution based on 3-probe calling
10 Validation Bank of 1,000s of known abnormal cases CNVs at limits of detection previously E.g. 2 probe calls Mosaics Many samples have data for: BlueGnome / Illumina 60K ISCA v2.0 Affymetrix CytoScan-HD and 750K SNP array Illumina CytoSNP SNP bead array 850K CHALLENGING CASES
11 DLR spread comparison; 48 sample validation Mean DLR: OGT v3 DDD = 0.115, Illumina v2 = 0.158
12 Deletion at 1q41-q42 8.7Mb deletion; mean log2 ratio, -0.9 Highly consistent probe behaviour; all 119 probes < -0.6
13 PDHA1 deletion (Xp22.2) 35 probes on v3 array Multi-exon 13kb deletion
14 MEF2C deletion (5q13.4) Manually called and validated from ISCA v2.0 array (2 probes only) 36 probes called on v3 array Minimum size 68kb; multiple exons
15 CREBBP (Rubenstein-Taybi) deletion (16p22.2) Manually called and validated from ISCA v2.0 array (2 probes only) 9 probes called on v3 array Minimum size 2.2kb; 2 exons
16 MID1 (Opitz-G) intragenic duplication (single exon) Previous detection by 2x105k OGT X-array 4 probes called on DDD array Minimum size 500bp (single exon)
17 MID1 (Opitz-G) intragenic duplication (single exon) Previous detection by 2x105k OGT X-array 4 probes called on v3 array Minimum size 500bp (single exon)
18 Investigations 46 XY 22q- FISH: NAD (brothers) Opitz-G? MID1 seq ( Naples 2006): NAD 1Mb BAC array: NAD X/Y tiling BAC array: NAD OGT X exon array; intragenic dup DDD acgh: NAD DDD exome: intragenic dup
19 TBX5 12q24 deletion (Holt-Oram) Minimum 450bp 3 probes, 1 exon
20 Mosaic trisomy 18? Low level mosaic on peripheral blood in IUGR neonate Confirmation on buccal swab
21 Mosaic trisomy 18? Aneuploidy summary plot Low level mosaic on peripheral blood in IUGR neonate Confirmation on buccal swab
22 Validation of CNVs from DDD
23 Validation of CNVs from DDD 12,000 undiagnosed UK trios recruited Majority had routine acgh in local centres WES and ultra-high resolution acgh at Wellcome Trust Sanger Institute, Cambridge Plausible pathogenic data fed-back to local clinical/laboratory teams for validation 1200 trios from WM region 300 variants so far (SNVs and CNVs)
24 DDD Research Report
25
26 Array-CGH (2x1m Agilent custom) De novo 1.27kb deletion
27 HDAC8 deletion confirmation 1.17kb deletion (minimum) 2 exons, 7 probes
28 HDAC8 deletion confirmation 1.17kb deletion (minimum) 2 exons, 7 probes
29 Predictive comparison in UCSC Platform Min Max OGT /DDD v3.0 Illumina 850k CytoScan HD
30
31 DDD validation Case 2: History Intellectual disability (severe) Autistic Self-mutilation Ptosis
32 DDD Research Report
33
34 De novo 3.8kb Array-CGH (2x1m Agilent custom) De novo 3.8kb deletion
35 MED13L deletion confirmation 269bp deletion (minimum) 1 exon (9), 3 probes
36 MED13L deletion confirmation 269bp deletion (minimum) 1 exon(9), 3 probes
37 MED13L deletion confirmation 269bp deletion (minimum) 1 exon(9), 3 probes
38 Predictive comparison in UCSC Platform Min Max OGT /DDD v3.0 Illumina 850k CytoScan HD
39
40 DDD validations Genotype-phenotype discussion in local MDT Both de novo cases fit clinical phenotypes Clinical reports issued Rapid, cost-effective validations Answers would have been possible for families years previously via acgh if DDD array had been available..
41 Prospective exonic CNV diagnoses (OGT/DDD array implemented April 2016)
42 Single exon deletion (1.2kb); ARSE Dysmorphic Skeletal anomalies Parental samples requested Chrondrodysplasia Punctata (X-linked)
43 Single exon deletion (1.2kb); ARSE
44 Single exon (1kb) PTPN11 dysmorphic?vsd/asd puffy hands/feet short 5th fingers Parental samples requested
45 Single exon (1kb) PTPN11 dysmorphic?vsd/asd puffy hands/feet short 5th fingers Parental samples requested
46 Single exon (1kb) PTPN11
47 PTPN11; DECIPHER
48 Single exon (1.1kb) GRIN2A ILD Motor delay DE NOVO
49 Balancing factors Exonic deletions SNPs: AOH/UPD
50 Application of v3 4x180K SNP array Unusual case of autosomal recessive Bartter syndrome Clinician; Homozygous deletion via UPD event? Bartter syndrome type 4B Renal salt wasting Deafness CLCNKA and CLCNKB Bartter syndrome type 3 Renal salt wasting CLCNKB
51 Chr1 (whole chromosome)
52 Chr1 (whole chromosome) Regions of UPD (AOH)
53 Homozygous deletion in region of UPD 1p36.13
54 Homozygous deletion in region of UPD 1p36.13 Algorithmic deletion call Deleted probes only mapped to CLCNKB; NO probes in CLCNKA
55
56 OGT/DDD v3 180k SNP Beta test data
57 OGT/DDD v3 180k SNP Beta test data CLCNKA not deleted No deafness Bartter Type 3
58 Summary OGT/DDD 8x60k implemented all referrals Single exon deletions can be detected if targeted Will detection rate increase? 3/400 (0.75%) WM DDD cases have pathogenic single exon changes >7/1500 (>0.5%) prospective cases missed previously? How much has been missed? High density does not equate to high resolution New genes = future versions? BUT have the majority of haploinsufficient genes now been discovered? Prevalence and architecture of dominant developmental disorders
59 Summary Extended life for chromosomal microarray? Rapid, cost-effective detection of recurrent CNV syndromes Exome/panel CNV calling improvements? CNV calling in WGS / 100kgp data? Need for higher resolution data-sets ExAC CNV data released August 2016 Clinical CNV data
60 Data-sharing NHS Data-sharing consortium (semi) auto-upload capability to DECIPHER OGT software export plug-in Auto-upload via API functionality being explored SNV and CNV worlds are colliding Interpretation requires all variattion THIS DATA NEEDS SHARING
61 NHS Data-sharing Consortium
62 Data Collection How common are smaller exonic changes? e.g <3 exons What has been missed? Unusual mechanisms/ genotype-phenotype? This UGM as a forum to drive data-collection project OGT keen to support collaborative study DDD team keen to collaborate on joint publication
63 Acknowledgements WMRGL team Rowena Roberts Lisa Reali, Sam Martin, Dave Bohanna, Laura Scott, Gareth Masson, Fiona Togneri DDD / DECIPHER team OGT team Thank-you for your attention!!
Challenges of CGH array testing in children with developmental delay. Dr Sally Davies 17 th September 2014
Challenges of CGH array testing in children with developmental delay Dr Sally Davies 17 th September 2014 CGH array What is CGH array? Understanding the test Benefits Results to expect Consent issues Ethical
More informationApproach to Mental Retardation and Developmental Delay. SR Ghaffari MSc MD PhD
Approach to Mental Retardation and Developmental Delay SR Ghaffari MSc MD PhD Introduction Objectives Definition of MR and DD Classification Epidemiology (prevalence, recurrence risk, ) Etiology Importance
More informationSNP Array NOTE: THIS IS A SAMPLE REPORT AND MAY NOT REFLECT ACTUAL PATIENT DATA. FORMAT AND/OR CONTENT MAY BE UPDATED PERIODICALLY.
SAMPLE REPORT SNP Array NOTE: THIS IS A SAMPLE REPORT AND MAY NOT REFLECT ACTUAL PATIENT DATA. FORMAT AND/OR CONTENT MAY BE UPDATED PERIODICALLY. RESULTS SNP Array Copy Number Variations Result: GAIN,
More informationApplications of Chromosomal Microarray Analysis (CMA) in pre- and postnatal Diagnostic: advantages, limitations and concerns
Applications of Chromosomal Microarray Analysis (CMA) in pre- and postnatal Diagnostic: advantages, limitations and concerns جواد کریمزاد حق PhD of Medical Genetics آزمايشگاه پاتوبيولوژي و ژنتيك پارسه
More informationSNP Array NOTE: THIS IS A SAMPLE REPORT AND MAY NOT REFLECT ACTUAL PATIENT DATA. FORMAT AND/OR CONTENT MAY BE UPDATED PERIODICALLY.
SAMPLE REPORT SNP Array NOTE: THIS IS A SAMPLE REPORT AND MAY NOT REFLECT ACTUAL PATIENT DATA. FORMAT AND/OR CONTENT MAY BE UPDATED PERIODICALLY. RESULTS SNP Array Copy Number Variations Result: LOSS,
More informationMultiple Copy Number Variations in a Patient with Developmental Delay ASCLS- March 31, 2016
Multiple Copy Number Variations in a Patient with Developmental Delay ASCLS- March 31, 2016 Marwan Tayeh, PhD, FACMG Director, MMGL Molecular Genetics Assistant Professor of Pediatrics Department of Pediatrics
More informationWhat s the Human Genome Project Got to Do with Developmental Disabilities?
What s the Human Genome Project Got to Do with Developmental Disabilities? Disclosures Neither speaker has anything to disclose. Phase Two: Interpretation Officially started in October 1990 Goals of the
More informationCURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE. Dr. Bahar Naghavi
2 CURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE Dr. Bahar Naghavi Assistant professor of Basic Science Department, Shahid Beheshti University of Medical Sciences, Tehran,Iran 3 Introduction Over 4000
More informationCHROMOSOMAL MICROARRAY (CGH+SNP)
Chromosome imbalances are a significant cause of developmental delay, mental retardation, autism spectrum disorders, dysmorphic features and/or birth defects. The imbalance of genetic material may be due
More informationCytogenetics 101: Clinical Research and Molecular Genetic Technologies
Cytogenetics 101: Clinical Research and Molecular Genetic Technologies Topics for Today s Presentation 1 Classical vs Molecular Cytogenetics 2 What acgh? 3 What is FISH? 4 What is NGS? 5 How can these
More informationGenetic Counselling in relation to genetic testing
Genetic Counselling in relation to genetic testing Dr Julie Vogt Consultant Geneticist West Midlands Regional Genetics Service September 2016 Disclosures for Research Support/P.I. Employee Consultant Major
More informationGenetic Testing for the Developmental Delay/Intellectual Disability, Autism Spectrum Disorder, and Congenital Anomalies
Genetic Testing for the Developmental Delay/Intellectual Disability, Autism Spectrum Disorder, and Congenital Anomalies Policy Number: 2.04.59 Last Review: 5/2018 Origination: 5/2015 Next Review: 5/2019
More informationClinical evaluation of microarray data
Clinical evaluation of microarray data David Amor 19 th June 2011 Single base change Microarrays 3-4Mb What is a microarray? Up to 10 6 bits of Information!! Highly multiplexed FISH hybridisations. Microarray
More informationIdentifying Mutations Responsible for Rare Disorders Using New Technologies
Identifying Mutations Responsible for Rare Disorders Using New Technologies Jacek Majewski, Department of Human Genetics, McGill University, Montreal, QC Canada Mendelian Diseases Clear mode of inheritance
More informationNHS Array Service. ACC Audit 2009
NHS Array Service ACC Audit 2009 Kim Smith ACC Audit of arrays in diagnostics NHS Diagnostic Laboratories 2008 audit Regional Genetic Centres (24 centres) Specialist Haematological Cytogenetics Laboratories
More informationUpdating penetrance estimates for syndromes with variable phenotypic manifestation. Adele Corrigan June 27th
Updating penetrance estimates for syndromes with variable phenotypic manifestation Adele Corrigan June 27th Background Array CGH has led to increased identification of copy number variants (CNVs) Our understanding
More informationRACP Congress 2017 Genetics of Intellectual Disability and Autism: Past Present and Future 9 th May 2017
RACP Congress 2017 Genetics of Intellectual Disability and Autism: Past Present and Future 9 th May 2017 Why causation? Explanation for family Prognosis Recurrence risk and reproductive options Guide medical
More informationSection: Medicine Effective Date: January15, 2016 Subsection: Pathology/Laboratory Original Policy Date: December 7, 2011 Subject:
Section: Medicine Effective Date: January15, 2016 Last Review Status/Date: December 2015 Page: 1 of 22 Microarray Analysis and Next-Generation Autism Spectrum Disorder and/or Congenital Description Chromosomal
More informationSharan Goobie, MD, MSc, FRCPC
Sharan Goobie, MD, MSc, FRCPC Chromosome testing in 2014 Presenter Disclosure: Sharan Goobie has no potential for conflict of interest with this presentation Objectives Review of standard genetic investigations
More informationClinical Interpretation of Cancer Genomes
IGENZ Ltd, Auckland, New Zealand Clinical Interpretation of Cancer Genomes Dr Amanda Dixon-McIver www.igenz.co.nz 1992 Slovenia and Croatia gain independence USA and Russia declare the Cold War over Steffi
More informationGlobal variation in copy number in the human genome
Global variation in copy number in the human genome Redon et. al. Nature 444:444-454 (2006) 12.03.2007 Tarmo Puurand Study 270 individuals (HapMap collection) Affymetrix 500K Whole Genome TilePath (WGTP)
More informationGenomic structural variation
Genomic structural variation Mario Cáceres The new genomic variation DNA sequence differs across individuals much more than researchers had suspected through structural changes A huge amount of structural
More informationThe Deciphering Development Disorders (DDD) project: What a genomic approach can achieve
The Deciphering Development Disorders (DDD) project: What a genomic approach can achieve RCP ADVANCED MEDICINE, LONDON FEB 5 TH 2018 HELEN FIRTH DM FRCP DCH, SANGER INSTITUTE 3,000,000,000 bases in each
More informationInvestigating rare diseases with Agilent NGS solutions
Investigating rare diseases with Agilent NGS solutions Chitra Kotwaliwale, Ph.D. 1 Rare diseases affect 350 million people worldwide 7,000 rare diseases 80% are genetic 60 million affected in the US, Europe
More informationHuman Genetic Variation Copy Number Variation
The Evolution of Laboratory Prenatal Diagnosis Lawrence D. Platt, MD Professor of Obstetrics and Gynecology David Geffen School of Medicine at UCLA Center for Fetal Medicine & Women s Ultrasound Los Angeles,
More informationChromosome Microarray Analysis (CMA)
Chromosome Microarray Analysis (CMA) Ina E. Amarillo, PhD FACMG Cytogenomics Lab (Associate Medical Director) Pathology (Assistant Professor) OUTLINE Clinical Indications for Cytogenomics Testing Cytogenomics
More informationPractical challenges that copy number variation and whole genome sequencing create for genetic diagnostic labs
Practical challenges that copy number variation and whole genome sequencing create for genetic diagnostic labs Joris Vermeesch, Center for Human Genetics K.U.Leuven, Belgium ESHG June 11, 2010 When and
More informationGenetics and Genomics: Applications to Developmental Disability
Tuesday, 12:30 2:00, B1 Objective: Genetics and Genomics: Applications to Developmental Disability Helga Toriello 616-234-2712 toriello@msu.edu Identify advances in clinical assessment and management of
More informationCentoXome FUTURE'S KNOWLEDGE APPLIED TODAY
CentoXome FUTURE'S KNOWLEDGE APPLIED TODAY More genetic information requires cutting-edge interpretation techniques Whole Exome Sequencing For certain patients the combination of symptoms does not allow
More informationCentoXome FUTURE'S KNOWLEDGE APPLIED TODAY
CentoXome FUTURE'S KNOWLEDGE APPLIED TODAY More genetic information requires cutting-edge interpretation techniques Whole Exome Sequencing For some patients, the combination of symptoms does not allow
More informationAdvance Your Genomic Research Using Targeted Resequencing with SeqCap EZ Library
Advance Your Genomic Research Using Targeted Resequencing with SeqCap EZ Library Marilou Wijdicks International Product Manager Research For Life Science Research Only. Not for Use in Diagnostic Procedures.
More informationPrenatal Diagnosis: Are There Microarrays in Your Future?
Financial Disclosure UCSF Antepartum Intrapartum Management Course June 8 I have no financial relationship with any aspect of private industry Prenatal Diagnosis: Are There Microarrays in Your Future?
More informationFaravareh Khordadpoor (PhD in molecular genetics) 1- Tehran Medical Genetics Laboratory 2- Science and research branch, Islamic Azad University
Faravareh Khordadpoor (PhD in molecular genetics) 1- Tehran Medical Genetics Laboratory 2- Science and research branch, Islamic Azad University 1395 21 مشاوره ژنتیک و نقش آن در پیش گیری از معلولیت ها 20
More informationSEAMLESS CGH DIAGNOSTIC TESTING
SEAMLESS CGH DIAGNOSTIC TESTING GENETISURE DX POSTNATAL ASSAY Informed decisions start with a complete microarray platform for postnatal analysis For In Vitro Diagnostic Use INTENDED USE: GenetiSure Dx
More informationGenetics update and implications for (General) Practice
Genetics update and implications for (General) Practice May 12 th 2018 Women s Health Symposium Clearwater Estate Dr Kate Gibson MB BCh, MRCP, FRACP Topics NZ Clinical Genetics delivery New Technologies
More informationChromosome microarray analysis in routine prenatal diagnosis practice: a prospective study on 3000 consecutive clinical cases
Chromosome microarray analysis in routine prenatal diagnosis practice: a prospective study on 3000 consecutive clinical cases Fiorentino F, Napoletano S, Caiazzo F, Sessa M, Bono S, Spizzichino L, Gordon
More informationMultiplex target enrichment using DNA indexing for ultra-high throughput variant detection
Multiplex target enrichment using DNA indexing for ultra-high throughput variant detection Dr Elaine Kenny Neuropsychiatric Genetics Research Group Institute of Molecular Medicine Trinity College Dublin
More informationAgilent s Copy Number Variation (CNV) Portfolio
Technical Overview Agilent s Copy Number Variation (CNV) Portfolio Abstract Copy Number Variation (CNV) is now recognized as a prevalent form of structural variation in the genome contributing to human
More informationCNV Detection and Interpretation in Genomic Data
CNV Detection and Interpretation in Genomic Data Benjamin W. Darbro, M.D., Ph.D. Assistant Professor of Pediatrics Director of the Shivanand R. Patil Cytogenetics and Molecular Laboratory Overview What
More informationDeciphering Developmental Disorders (DDD) DDG2P
Deciphering Developmental Disorders (DDD) DDG2P David FitzPatrick MRC Human Genetics Unit, University of Edinburgh Deciphering Developmental Disorders objectives research understand genetics of DD translation
More informationAssociation for Molecular Pathology Promoting Clinical Practice, Basic Research, and Education in Molecular Pathology
Association for Molecular Pathology Promoting Clinical Practice, Basic Research, and Education in Molecular Pathology 9650 Rockville Pike, Bethesda, Maryland 20814 Tel: 301-634-7939 Fax: 301-634-7990 Email:
More informationHow many disease-causing variants in a normal person? Matthew Hurles
How many disease-causing variants in a normal person? Matthew Hurles Summary What is in a genome? What is normal? Depends on age What is a disease-causing variant? Different classes of variation Final
More informationCHROMOSOME MICROARRAY TESTING
CHROMOSOME MICROARRAY TESTING UnitedHealthcare Commercial Medical Policy Policy Number: 2017T0559J Effective Date: August 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationNational Medical Policy
National Medical Policy Subject: Policy Number: Single Nucleotide Polymorphism (SNP) Chromosomal Microarray Analysis for Prenatal Testing and Intellectual Disability, Developmental Delay, and Multiple
More informationClinical Genomics. Ina E. Amarillo, PhD FACMGG
Clinical Genomics Ina E. Amarillo, PhD FACMGG Associate Medical Director, Cytogenetics Lab (CaTG), Lab and Genomic Medicine Assistant Professor, Pathology and Immunology Outline Clinical Genomics Testing
More informationCopy Number Variants of Uncertain Significance in Prenatal diagnosis Are the Goalposts Moving? Lisa Burvill-Holmes Bristol Genetics Laboratory
Copy Number Variants of Uncertain Significance in Prenatal diagnosis Are the Goalposts Moving? Lisa Burvill-Holmes Bristol Genetics Laboratory http://www.nbt.nhs.uk/genetics Microarray CGH in Prenatal
More informationGenetic Testing 101: Interpreting the Chromosomes
Genetic Testing 101: Interpreting the Chromosomes Kristin Lindstrom, MD Division of Genetics and Metabolism Phoenix Children s Hospital AzAAP Pediatrics in the Red Rocks I have no disclosures for this
More informationLarge-scale discovery of novel genetic causes of developmental disorders
1 Large-scale discovery of novel genetic causes of developmental disorders The Deciphering Developmental Disorders Study Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge,
More informationThe role of cytogenomics in the diagnostic work-up of Chronic Lymphocytic Leukaemia
The role of cytogenomics in the diagnostic work-up of Chronic Lymphocytic Leukaemia Adrian Zordan, Meaghan Wall, Ruth MacKinnon, Pina D Achille & Lynda Campbell Victorian Cancer Cytogenetics Service (VCCS)
More informationGenerating Spontaneous Copy Number Variants (CNVs) Jennifer Freeman Assistant Professor of Toxicology School of Health Sciences Purdue University
Role of Chemical lexposure in Generating Spontaneous Copy Number Variants (CNVs) Jennifer Freeman Assistant Professor of Toxicology School of Health Sciences Purdue University CNV Discovery Reference Genetic
More information100,000 genomes RD Validation and Reporting Working Groups - Overview - Dom McMullan Chair Association for Clinical Genomic Science
100,000 genomes RD Validation and Reporting Working Groups - Overview - Dom McMullan Chair Association for Clinical Genomic Science What? More Working Groups? Post January 20 th meeting Volunteers for
More informationNature Genetics: doi: /ng Supplementary Figure 1. PCA for ancestry in SNV data.
Supplementary Figure 1 PCA for ancestry in SNV data. (a) EIGENSTRAT principal-component analysis (PCA) of SNV genotype data on all samples. (b) PCA of only proband SNV genotype data. (c) PCA of SNV genotype
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): April 26, 2011 Most Recent Review Date (Revised): January 28, 2014 Effective Date: June 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationComprehensive performance comparison of high-resolution array platforms for genome-wide Copy Number Variation (CNV) analysis in humans
Haraksingh et al. BMC Genomics (2017) 18:321 DOI 10.1186/s12864-017-3658-x RESEARCH ARTICLE Comprehensive performance comparison of high-resolution array platforms for genome-wide Copy Number Variation
More informationAddressing the challenges of genomic characterization of hematologic malignancies using microarrays
Addressing the challenges of genomic characterization of hematologic malignancies using microarrays Sarah South, PhD, FACMG Medical Director, ARUP Laboratories Department of Pediatrics and Pathology University
More informationMedical Policy. MP Invasive Prenatal (Fetal) Diagnostic Testing
Medical Policy MP 2.04.116 BCBSA Ref. Policy: 2.04.116 Last Review: 04/30/2018 Effective Date: 04/30/2018 Section: Medicine Related Policies 2.04.59 Genetic Testing for Developmental Delay/Intellectual
More informationMerging single gene-level CNV with sequence variant interpretation following the ACMGG/AMP sequence variant guidelines
Merging single gene-level CNV with sequence variant interpretation following the ACMGG/AMP sequence variant guidelines Tracy Brandt, Ph.D., FACMG Disclosure I am an employee of GeneDx, Inc., a wholly-owned
More informationGeneral Nuts and Bolts of Genetics
General Nuts and Bolts of Genetics Michael J. Gambello, MD, PhD Section Chief, Division of Medical Genetics Primer in Genetics Chromosomes: 46, XX or 46, XY. 23 chromosomes from mother, 23 from father.
More informationDNA-seq Bioinformatics Analysis: Copy Number Variation
DNA-seq Bioinformatics Analysis: Copy Number Variation Elodie Girard elodie.girard@curie.fr U900 institut Curie, INSERM, Mines ParisTech, PSL Research University Paris, France NGS Applications 5C HiC DNA-seq
More informationTHE PENNSYLVANIA STATE UNIVERSITY SCHREYER HONORS COLLEGE DEPARTMENT OF BIOCHEMISTRY AND MOLECULAR BIOLOGY
THE PENNSYLVANIA STATE UNIVERSITY SCHREYER HONORS COLLEGE DEPARTMENT OF BIOCHEMISTRY AND MOLECULAR BIOLOGY GENOME-WIDE MICROARRAY ANALYSIS IN A CASE-CONTROL STUDY REVEALS EVELATED LEVEL OF GLOBAL COPY
More informationNovember 9, Johns Hopkins School of Medicine, Baltimore, MD,
Fast detection of de-novo copy number variants from case-parent SNP arrays identifies a deletion on chromosome 7p14.1 associated with non-syndromic isolated cleft lip/palate Samuel G. Younkin 1, Robert
More informationSupplementary note: Comparison of deletion variants identified in this study and four earlier studies
Supplementary note: Comparison of deletion variants identified in this study and four earlier studies Here we compare the results of this study to potentially overlapping results from four earlier studies
More informationIntroduction to genetic variation. He Zhang Bioinformatics Core Facility 6/22/2016
Introduction to genetic variation He Zhang Bioinformatics Core Facility 6/22/2016 Outline Basic concepts of genetic variation Genetic variation in human populations Variation and genetic disorders Databases
More informationWhat lies beneath: challenges in reporting SNP array results. Jonathan Waters
What lies beneath: challenges in reporting SNP array results Jonathan Waters Challenges in variant interpretation Austin Court, Birmingham Monday 4 th July 2016 What lies beneath: challenges in reporting
More informationUnderstanding The Genetics of Diamond Blackfan Anemia
Understanding The Genetics of Diamond Blackfan Anemia Jason Farrar, MD jefarrar@ About Me Assistant Professor of Pediatrics at University of Arkansas for Medical Sciences & Arkansas Children s Hospital
More informationImproving genomic diagnoses through accurate, specific phenotype information
Improving genomic diagnoses through accurate, specific phenotype information Lisa Ewans Clinical Geneticist, RPAH, Sydney PhD student in genomics, KCCG, Garvan; UNSW https://vlab.org Overview Phenotype
More informationMP Genetic Testing for Developmental Delay/Intellectual Disability, Autism Spectrum Disorder, and Congenital Anomalies
Medical Policy Genetic Testing for Developmental Delay/Intellectual Disability, Autism Spectrum Disorder, and Congenital BCBSA Ref. Policy: 2.04.59 Last Review: 10/18/2018 Effective Date: 10/18/2018 Section:
More informationGenetic Testing for Single-Gene and Multifactorial Conditions
Clinical Appropriateness Guidelines Genetic Testing for Single-Gene and Multifactorial Conditions EFFECTIVE DECEMBER 1, 2017 Appropriate.Safe.Affordable 2017 AIM Specialty Health 2069-1217 Table of Contents
More informationGenetics and Genetic Testing for Autism:
STAR Training 2/22/2018 Genetics and Genetic Testing for Autism: Demystifying the Journey to Find a Cause Alyssa (Ah leesa) Blesson, MGC, CGC Certified Genetic Counselor Center for Autism and Related Disorders
More informationProtocol. Genetic Testing for Developmental Delay and Autism Spectrum Disorder
Genetic Testing for Developmental Delay and Autism Spectrum (20459, 20483, 20481) Medical Benefit Effective Date: 01/01/18 Next Review Date: 09/18 Preauthorization Yes Review Dates: 09/10, 09/11, 03/12,
More informationMP Whole Exome and Whole Genome Sequencing for Diagnosis of Genetic Disorders
Medical Policy BCBSA Ref. Policy: 2.04.102 Last Review: 10/18/2018 Effective Date: 10/18/2018 Section: Medicine Related Policies 2.04.59 Genetic Testing for Developmental Delay/Intellectual Disability,
More informationWhy did this happen? Genetic and teratologic considerations in CHD Jennifer Kussmann, MS,CGC. The Children's Mercy Hospital, 2014.
Why did this happen? Genetic and teratologic considerations in CHD Jennifer Kussmann, MS,CGC The Children's Mercy Hospital, 2014. 03/14 Risk factors Family history Maternal medical condition/ illness Monochorionic
More informationCorporate Medical Policy
Corporate Medical Policy Invasive Prenatal (Fetal) Diagnostic Testing File Name: Origination: Last CAP Review: Next CAP Review: Last Review: invasive_prenatal_(fetal)_diagnostic_testing 12/2014 3/2018
More informationNature Biotechnology: doi: /nbt.1904
Supplementary Information Comparison between assembly-based SV calls and array CGH results Genome-wide array assessment of copy number changes, such as array comparative genomic hybridization (acgh), is
More informationUTILIZATION OF A SNP MICROARRAY FOR CHRONIC LYMPHOCYTIC LEUKEMIA: EFFICACY, INFORMATIVE FINDINGS AND PROGNOSTIC CAPABILITIES
UTILIZATION OF A SNP MICROARRAY FOR CHRONIC LYMPHOCYTIC LEUKEMIA: EFFICACY, INFORMATIVE FINDINGS AND PROGNOSTIC CAPABILITIES S Schwartz, Z Hosseini, S Schepis, P Papenhausen Laboratory Corporation of America
More informationThe 100,000 Genomes Project Harnessing the power of genomics for NHS rare disease and cancer patients
The 100,000 Genomes Project Harnessing the power of genomics for NHS rare disease and cancer patients Dr Richard Scott, Clinical Lead for Rare Disease Dr Nirupa Murugaesu, Clinical Lead for Cancer Four
More informationNew and Developing Technologies for Genetic Diagnostics National Genetics Reference Laboratory (Wessex) Salisbury, UK - July 2010 BACs on Beads
New and Developing Technologies for Genetic Diagnostics National Genetics Reference Laboratory (Wessex) Salisbury, UK - July 2010 BACs on Beads Susan Gross, MD Division of Reproductive Genetics Professor
More informationApproach to the Genetic Diagnosis of Neurological Disorders
Approach to the Genetic Diagnosis of Neurological Disorders Dr Wendy Jones MBBS MRCP Great Ormond Street Hospital for Children National Hospital for Neurology and Neurosurgery What is a genetic diagnosis?
More informationComprehensive Chromosome Screening Is NextGen Likely to be the Final Best Platform and What are its Advantages and Quirks?
Comprehensive Chromosome Screening Is NextGen Likely to be the Final Best Platform and What are its Advantages and Quirks? Embryo 1 Embryo 2 combine samples for a single sequencing chip Barcode 1 CTAAGGTAAC
More informationRare Disease Research and the UK 100,000 Genome Project
Rare Disease Research and the UK 100,000 Genome Project Prof F Lucy Raymond MA DPhil FRCP Department of Medical Genetics University of Cambridge UK Flr24@cam.ac.uk Copenhagen October Precision Medicine
More informationMEDICAL GENOMICS LABORATORY. Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG)
Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG) Ordering Information Acceptable specimen types: Fresh blood sample (3-6 ml EDTA; no time limitations associated with receipt)
More informationUnderstanding DNA Copy Number Data
Understanding DNA Copy Number Data Adam B. Olshen Department of Epidemiology and Biostatistics Helen Diller Family Comprehensive Cancer Center University of California, San Francisco http://cc.ucsf.edu/people/olshena_adam.php
More informationDr Dipti Deshmukh. Mayu Uemura. 11th September Introduction
Genetic Findings in Children with Unexplained Developmental Delay Dr Dipti Deshmukh Neurodevelopmental Consultant, St. George's Hospital, London Mayu Uemura 4th year MBBS4, St George s University of London
More informationRecurrent de novo mutations in neurodevelopmental disorders: properties and clinical implications
Wilfert et al. Genome Medicine (2017) 9:101 DOI 10.1186/s13073-017-0498-x REVIEW Recurrent de novo mutations in neurodevelopmental disorders: properties and clinical implications Amy B. Wilfert 1, Arvis
More informationPrior Authorization Review Panel MCO Policy Submission
Prior Authorization Review Panel MCO Policy Submission A separate copy of this form must accompany each policy submitted for review. Policies submitted without this form will not be considered for review.
More informationK. COHEN*, A. TZIKA, H. WOOD, S. BERRI, P. ROBERTS, G. MASON* and E. SHERIDAN
Ultrasound Obstet Gynecol 05; 45: 94 40 Published online in Wiley Online Library (wileyonlinelibrary.com). DOI: 0.00/uog.4767 Diagnosis of fetal submicroscopic chromosomal abnormalities in failed array
More informationInvasive Prenatal (Fetal) Diagnostic Testing
Protocol Invasive Prenatal (Fetal) Diagnostic Testing (204116) Medical Benefit Effective Date: 04/01/18 Next Review Date: 01/19 Preauthorization Yes Review Dates: 01/15, 01/16, 01/17, 01/18 Preauthorization
More information22q11.2 DELETION SYNDROME. Anna Mª Cueto González Clinical Geneticist Programa de Medicina Molecular y Genética Hospital Vall d Hebrón (Barcelona)
22q11.2 DELETION SYNDROME Anna Mª Cueto González Clinical Geneticist Programa de Medicina Molecular y Genética Hospital Vall d Hebrón (Barcelona) Genomic disorders GENOMICS DISORDERS refers to those diseases
More informationVan test naar diagnose naar
Van test naar diagnose naar V therapie op maat Marjolein Kriek, LUMC Joris Veltman, RUNMC Exome diagnostics in genetically heterogeneous disease Joris Veltman, PhD Department of Human Genetics Radboud
More informationLTA Analysis of HapMap Genotype Data
LTA Analysis of HapMap Genotype Data Introduction. This supplement to Global variation in copy number in the human genome, by Redon et al., describes the details of the LTA analysis used to screen HapMap
More informationSETPEG GENETIC TESTING GUIDELINES Version 1.0, 5 th October 2017
SETPEG GENETIC TESTING GUIDELINES Version 1.0, 5 th October 2017 1. The Epilepsy Genetic Diagnostic & Counselling Service at King s Health Partners Professor Deb Pal PhD MRCP (Consultant) deb.pal@nhs.net
More informationIntroduction to Fetal Medicine: Genetics and Embryology
Introduction to Fetal Medicine: Genetics and Embryology Question: What do cancer biology, molecular biology, neurobiology, cell biology developmental biology and reproductive biology, all have in common?
More informationClinical Policy Title: Array comparative genomic hybridization testing
Clinical Policy Title: Array comparative genomic hybridization testing Clinical Policy Number: 02.01.03 Policy contains: Chromosomal microarray analysis. Effective Date: September 1, 2015 Comparative genomic
More informationCost effective, computer-aided analytical performance evaluation of chromosomal microarrays for clinical laboratories
University of Iowa Iowa Research Online Theses and Dissertations Summer 2012 Cost effective, computer-aided analytical performance evaluation of chromosomal microarrays for clinical laboratories Corey
More informationIncreasing the Sensitivity of Genomic Assays Permits a Higher Resolution Study of the Human Genome. Our Current Knowledge of Genetics and Genomics
Our Current Knowledge of Genetics and Genomics Unlocking the Diagnostic Potential of Genomic Medicine The Beaumont DNA Array Experience Mark Micale, Ph.D., F.A.C.M.G. Medical Director, Clinical Cytogenomics
More informationAbstract. Optimization strategy of Copy Number Variant calling using Multiplicom solutions APPLICATION NOTE. Introduction
Optimization strategy of Copy Number Variant calling using Multiplicom solutions Michael Vyverman, PhD; Laura Standaert, PhD and Wouter Bossuyt, PhD Abstract Copy number variations (CNVs) represent a significant
More informationGenomic complexity and arrays in CLL. Gian Matteo Rigolin, MD, PhD St. Anna University Hospital Ferrara, Italy
Genomic complexity and arrays in CLL Gian Matteo Rigolin, MD, PhD St. Anna University Hospital Ferrara, Italy Clinical relevance of genomic complexity (GC) in CLL GC has been identified as a critical negative
More informationCHROMOSOME MICROARRAY TESTING (NON-ONCOLOGY CONDITIONS)
CHROMOSOME MICROARRAY TESTING (NON-ONCOLOGY CONDITIONS) UnitedHealthcare Oxford Clinical Policy Policy Number: LABORATORY 016.12 T2 Effective Date: June 1, 2018 Table of Contents Page INSTRUCTIONS FOR
More informationBenefits and pitfalls of new genetic tests
Benefits and pitfalls of new genetic tests Amanda Krause Division of Human Genetics, NHLS and University of the Witwatersrand Definition of Genetic Testing the analysis of human DNA, RNA, chromosomes,
More information